Robert Jan Baatenburg de Jong

Prof. Dr. Robert Jan Baatenburg de Jong

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SKStijn Keereweer
Stijn Keereweer
PDPieter B.A.A. Van Driel
Pieter B.A.A. Van Driel
TSThomas J.A. Snoeks
Thomas J.A. Snoeks
JKJeroen D.F. Kerrebijn
Jeroen D.F. Kerrebijn
RJRobert Jan Baatenburg de Jong
Robert Jan Baatenburg de Jong
CLClemens W.G.M. Löwik
Clemens W.G.M. Löwik
Optical image-guided cancer surgery is a promising technique to adequately determine tumor margins by tumor-specific targeting, potentially resulting in complete resection of tumor tissue with improved survival. However, identification of the photons coming from the fluorescent contrast agent is complicated by autofluorescence, optical tissue properties, and accurate fluorescent targeting agents and imaging systems. All these factors have an important influence on the image that is presented to the surgeon. Considering the clinical consequences at stake, it is a prerequisite to answer the questions that are essential for the surgeon. What is optical image-guided surgery and how can it improve patient care? What should the oncologic surgeon know about the fundamental principles of optical imaging to understand which conclusions can be drawn from the images? And how do the limitations influence clinical decision making? This article discusses these questions and provides a clear overview of the basic principles and practical applications. Although there are limitations to the intrinsic capacity of the technique, when practical and technical surgical possibilities are considered, optical imaging can be a very powerful intraoperative tool in guiding the future oncologic surgeon toward radical resection and optimal clinical results. Clin Cancer Res; 19(14); 3745–54. ©2013 AACR.

9 July 2010 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
SKStijn Keereweer
Stijn Keereweer
JKJeroen D. F. Kerrebijn
Jeroen D. F. Kerrebijn
PDPieter B. A. A. van Driel
Pieter B. A. A. van Driel
BXBangwen Xie
Bangwen Xie
EKEric L. Kaijzel
Eric L. Kaijzel
CLClemens W. G. M. Löwik
Clemens W. G. M. Löwik
In cancer surgery, intra-operative assessment of the tumor-free margin, which is critical for the prognosis of the patient, relies on the visual appearance and palpation of the tumor. Optical imaging techniques provide real-time visualization of the tumor, warranting intra-operative image-guided surgery. Within this field, imaging in the near-infrared light spectrum offers two essential advantages: increased tissue penetration of light and an increased signal-to-background-ratio of contrast agents. In this article, we review the various techniques, contrast agents, and camera systems that are currently used for image-guided surgery. Furthermore, we provide an overview of the wide range of molecular contrast agents targeting specific hallmarks of cancer and we describe perspectives on its future use in cancer surgery.

31 January 2011 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
EFEric Farrell
Eric Farrell
SBSanne K Both
Sanne K Both
KOKathrin I Odörfer
Kathrin I Odörfer
WKWendy Koevoet
Wendy Koevoet
NKNicole Kops
Nicole Kops
GOGerjo J.V.M. Van Osch
Gerjo J.V.M. Van Osch
Bone grafts are required to repair large bone defects after tumour resection or large trauma. The availability of patients' own bone tissue that can be used for these procedures is limited. Thus far bone tissue engineering has not lead to an implant which could be used as alternative in bone replacement surgery. This is mainly due to problems of vascularisation of the implanted tissues leading to core necrosis and implant failure. Recently it was discovered that embryonic stem cells can form bone via the endochondral pathway, thereby turning in-vitro created cartilage into bone in-vivo. In this study we investigated the potential of human adult mesenchymal stem cells to form bone via the endochondral pathway. MSCs were cultured for 28 days in chondrogenic, osteogenic or control medium prior to implantation. To further optimise this process we induced mineralisation in the chondrogenic constructs before implantation by changing to osteogenic medium during the last 7 days of culture. After 8 weeks of subcutaneous implantation in mice, bone and bone marrow formation was observed in 8 of 9 constructs cultured in chondrogenic medium. No bone was observed in any samples cultured in osteogenic medium. Switch to osteogenic medium for 7 days prevented formation of bone in-vivo. Addition of β-glycerophosphate to chondrogenic medium during the last 7 days in culture induced mineralisation of the matrix and still enabled formation of bone and marrow in both human and rat MSC cultures. To determine whether bone was formed by the host or by the implanted tissue we used an immunocompetent transgenic rat model. Thereby we found that osteoblasts in the bone were almost entirely of host origin but the osteocytes are of both host and donor origin. The preliminary data presented in this manuscript demonstrates that chondrogenic priming of MSCs leads to bone formation in vivo using both human and rat cells. Furthermore, addition of β-glycerophosphate to the chondrogenic medium did not hamper this process. Using transgenic animals we also demonstrated that both host and donor cells played a role in bone formation. In conclusion these data indicate that in-vitro chondrogenic differentiation of human MSCs could lead to an alternative and superior approach for bone tissue engineering.

5 September 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MRMichelle M. Rietbergen
Michelle M. Rietbergen
CLC. René Leemans
C. René Leemans
Elisabeth BloemenaElisabeth Bloemena
Elisabeth Bloemena
DHDaniëlle A.M. Heideman
Daniëlle A.M. Heideman
BBBoudewijn J.M. Braakhuis
Boudewijn J.M. Braakhuis
RBRuud H. Brakenhoff
Ruud H. Brakenhoff
Human papillomavirus (HPV) infection has been etiologically linked to oropharyngeal squamous cell carcinoma (OPSCC). The prevalence of HPV‐positive OPSCC varies between studies, ranging from 20 to 90%. This may be related to the lack of a standardized HPV detection assay as well as to the time period in which HPV prevalence is investigated, as rising incidence rates are reported over the last decades. Here, we validated our previously defined test algorithm for HPV detection in formalin‐fixed paraffin‐embedded (FFPE) tumor specimen consisting of p16INK4A immunostaining followed by high‐risk HPV DNA detection by GP5+/6+ PCR on the positive cases (Smeets et al., Int J Cancer 2007;121:2465–72). In addition, we analyzed HPV prevalence rates in OPSCCs in the years 1990–2010. The test algorithm was validated on a consecutive series of 86 OPSCCs collected during 2008–2011, of which both fresh frozen and FFPE samples were available. We performed HPV‐E6 RT‐PCR on the frozen samples as gold standard and applied the algorithm to the corresponding FFPE samples. The test algorithm showed an accuracy of 98%. Using the validated algorithm, we determined the presence of an oncogenic HPV infection in 240 OPSCCs of patients diagnosed in the years 1990–2010 at our center. A significant increase in the proportion of HPV‐positive samples was observed, from 5.1% in 1990 to 29.0% in 2010 (p = 0.001). In conclusion, we confirmed the accuracy of the test algorithm for HPV detection in FFPE tumor specimen and we found a significant increase in the prevalence of HPV in OPSCC over the last two decades at our center.

14 August 2013 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
MRM. M. Rietbergen
M. M. Rietbergen
RBRuud H. Brakenhoff
Ruud H. Brakenhoff
Elisabeth BloemenaElisabeth Bloemena
Elisabeth Bloemena
BWB. I. Witte
B. I. Witte
PSP. J. F. Snijders
P. J. F. Snijders
CLC. R. Leemans
C. R. Leemans
The presence of human papillomavirus (HPV)-infection in oropharyngeal squamous cell carcinoma (OPSCC) is a major determinant in prognostic risk modeling. However, most risk models are based on clinical trials which only include a selected patient population. The clinical significance of HPV and other prognostic factors in patients with OPSCC remains to be evaluated in a large, unselected cohort, which also includes patients with stage I/II disease and patients with severe comorbidity. All patients diagnosed with OPSCC in 2000–2006 in two Dutch university hospitals were included. The presence of an oncogenic HPV infection was determined by p16-immunostaining, followed by a high-risk HPV general primer 5+/6+ DNA PCR on the p16-positive cases. Cox regression analysis was carried out to compare survival rates between HPV-positive and HPV-negative patients and a prognostic model was generated by recursive partitioning. In total, 163 of 841 (19.4%) tumors were HPV-positive. Patients with HPV-positive OPSCC had a more favorable overall survival [73.5% versus 40.9% after 5 years; P < 0.001; hazard ratio = 0.34, 95% confidence interval (CI) 0.25–0.48] compared with patients with HPV-negative OPSCC. Patients with p16-positive but HPV DNA-negative tumors showed a significantly less favorable survival than patients with p16-positive and HPV DNA-positive tumors (P < 0.001). A prognostic model was developed in which patients were classified into three risk groups according to HPV status, nodal stage and comorbidity. [Harrell's concordance index of 0.68 (95% CI 0.65–0.71)]. Tumor HPV status is a strong and independent prognostic factor for survival among patients with OPSCC. A prognostic risk model was proposed, based on our large, unselected cohort of patients with HPV status, comorbidity and nodal stage being the important prognostic factors. In addition, this study emphasizes the importance of performing an HPV DNA-specific test besides p16-immunostaining.

11 July 2017 in The Analyst
Verified
Journal Article
Closed access
PDF file
ISInês P. Santos
Inês P. Santos
EBElisa M. Barroso
Elisa M. Barroso
TSTom C. Bakker Schut
Tom C. Bakker Schut
PCPeter J. Caspers
Peter J. Caspers
CLCornelia G. F. van Lanschot
Cornelia G. F. van Lanschot
SKSenada Koljenović
Senada Koljenović
This review summarizes actual clinical needs in oncology that can be addressed by Raman spectroscopy, provides results published in the last 10 years and analyses the current status of translation of these results into clinical practice.